<SEC-DOCUMENT>0001193125-25-321340.txt : 20251217
<SEC-HEADER>0001193125-25-321340.hdr.sgml : 20251217
<ACCEPTANCE-DATETIME>20251216194722
ACCESSION NUMBER:		0001193125-25-321340
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251216
FILED AS OF DATE:		20251217
DATE AS OF CHANGE:		20251216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251576947

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d31816d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December 16, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T
Rule&nbsp;101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not
applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d31816dex991.htm">Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment
 Continues at Robust Pace </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 16, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d31816dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31816snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Strong Operational Progress in Global <FONT STYLE="white-space:nowrap">TACTI-004</FONT>
<FONT STYLE="white-space:nowrap">(KEYNOTE-F91)</FONT> Phase III and Enrolment Continues at Robust Pace </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The registrational <FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III has enrolled 289 patients
globally, over 38% of the trial&#8217;s targeted enrolment</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Strong operational progress continues globally with over 120 activated clinical sites and 27 countries having
received full regulatory approvals including the United States</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the
third quarter of CY2026</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#8211; December</B><B></B><B>&nbsp;16, 2025</B><B> &#8211;</B> <U>Immutep Limited</U>
(ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8221; or &#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today reports strong operational progress in the
<FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91)</FONT> Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD&#8217;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA) <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab), and chemotherapy as first line therapy for advanced/metastatic <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registrational <FONT STYLE="white-space:nowrap">TACTI-004</FONT> trial has enrolled
289<I> </I>patients (over 38% of the trial&#8217;s targeted enrolment of 756 patients), and enrolment continues at a robust pace. Additionally, the number of activated clinical sites now exceeds 120 and 27 countries have received full regulatory
approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This includes the United States where the first of multiple clinical sites has received full regulatory clearance following the recent
completion of the <U>FDA&#8217;s Project Optimus</U> initiative and subsequent receipt of local and central Institutional Review Board (IRB) approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced on 9&nbsp;October 2025, <FONT STYLE="white-space:nowrap">TACTI-004</FONT> had enrolled the necessary 170 patients to conduct the futility
analysis that remains on track for the first quarter of CY2026. Furthermore, Immutep expects to complete patient enrolment in the third quarter of CY2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep Chief Executive Officer, Marc Voigt, said,</B> &#8220;We are very pleased with the strong operational progress of
<FONT STYLE="white-space:nowrap">TACTI-004</FONT> globally and the robust pace of recruitment. Growing interest in this pivotal trial has been enhanced by the recent licensing deal for efti in emerging markets with Dr Reddy&#8217;s. The Immutep team
is excited about further delivering on key milestones ahead, including the futility analysis and completion of patient enrolment.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TACTI-004</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">TACTI-004</FONT> (<B>T</B>wo<B>&nbsp;ACT</B>ive<B>&nbsp;I</B>mmunotherapies) is a randomised, double-blind, controlled Phase III study evaluating eftilagimod alfa (efti), a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with MSD&#8217;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA)
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab), and chemotherapy as first line therapy for patients with advanced
or metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer with no EGFR, ALK or ROS1 genomic tumour aberrations. The global trial will enrol approximately 756 patients regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression and with <FONT STYLE="white-space:nowrap">non-squamous</FONT> or squamous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31816snap2.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tumours at over 150 clinical sites in over 25 countries. Patients will be randomised 1:1 to receive either efti in combination with pembrolizumab and chemotherapy in the treatment arm or
pembrolizumab in combination with chemotherapy and placebo in the control arm. The study&#8217;s dual primary endpoints are progression-free survival and overall survival. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is a novel
immunotherapy that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class&nbsp;II pathway to fight cancer. As an MHC Class&nbsp;II agonist, its activation of APCs engages the adaptive and innate
immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signals&nbsp;&amp; cytokines that further
boost the immune system&#8217;s ability to combat cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in a pivotal Phase III trial called <FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91),</FONT> as well as head and neck squamous cell
carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy, radiotherapy,
and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a late-stage biotechnology
company developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT><B> </B><FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eleanor Pearson,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 9066 4071; <U>eleanor.pearson@sodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g31816snap2.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g31816snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31816snap1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !9 PT# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]/: "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M\&?]<[G_ -*IJRQ'\5G7@/\ =H?/\V?+_@'_ )2'77_8:U+_ -)YZ[9_[O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>4Y<T6>?A,PA0I*G-/3L<M\"O%MKX\_;?L?$5C%-!9ZGJ-_=11W  D56MIR
MP!(S]":NK%QH<K\C'#357&J:ZM_DSK?V^]&O_#7Q>\(^,XK=I+(VD42R$'9Y
M\$SR;2>V5=<>N#Z5GA6G!Q-\SBX5HU>G^1ZQX>_;^\#^(M6T32XM$URWO-1N
MH;5VN$A$,!=PI8L)"2!G/W1P.U8/"S2;N=L,SI3:C9W9YU^WI\+M7TOQ=I'Q
M-T6&26WC2*"\>)-QMIHF)BE;_9((7)X!0?WA6V%FFG39RYG1E&:KQ.A\-_\
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MZ\*G4D5KB\V'($TC%F7/?:"%SWVYK@K3]I-R1[V$HNA14'N>E5B=84 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MB*L)P2BSR\!A:M&JY5%96_5'V#7 >\% !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
* 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g31816snap2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31816snap2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# PX# 1$  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /._'?QQ\/\ @>\>Q;S=2U%/OP6N,1GT9B<
M^PR:VA2E+4\?%YI0PLN3>79'#Q_M60F;$GAJ18L_>6]!;'T\L?SK3V'F>6L^
M5]:?X_\  /2_ ?Q4T+XA*Z:?*\-[&NY[.X 60#U&"0P^A^N*QG3<-SV\)CZ.
M,T@[/LSL:S/1"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT7\J #[;)Z+^5 !]MD]%_*@ ^VR>B_E0 ?;9/1?RH /MLGHOY4 'VV3T7\J
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M'VN2)K"N_=_H>J?;9/1?RK ]\/MLGHOY4 'VV3T7\J *] !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MHKFVFCN+>9!)'+$P9'4C(8$<$$<Y%7*+@W&2LT1&49Q4X.Z>S)*DH* "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * .?\4^ M"\9(/[5L$GE486=2
M4D4>FX<X]CQ5QG*.QQXC!T,5_%C=]^IQL7[.7A:.<2--J4J9SY3SKM^G" _K
M6GMI'EK),*G>[^__ (!WWA_POI7A6T^S:58Q6<1^]L&6<^K,>3^)K)R<MSV*
M.'I8>/+2C9&I4G0% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >"_%#0+*]_
M:3^'&IOX9NM0CM(;D7FI1Z)-<11NRC[+OF6,KE7W$$M\F<G;G-;X64H1Q+B[
M-Q5NGO7UM_V[I?K\.NQYN/@ISP]XWM)WTO[MG:__ &]K;IOYG-^'?$?QCO[?
M1S?W?B"W>^TW5Y+K.BP)]EG@E;[)C-O\ID4 ;7SN'*C/-.IR1IU''5J$)+SD
M_BC^K2U7>QI>J\5"%VH2J3B]-HI7C*]ODF[I]F5M1\=?&JYT*]U*&WUJTO;;
M0M*O(K"#0T*3WCR[;J(AX6<D*<LJL"N,\"NJ-.A[=Q;]UU$M]H.-V[]D^K]&
M<BJ8J5--W3]G)[?;4G9;;M6TZ[HVY?&/Q4T;XB_99UUF]\)6GB%();L:*)99
MK.2VW<>5#\T:2_+O1<C.&8URTU"5-.6]JB^::Y&^UUZ1?8NI4Q$9RY;V3I/;
MI)/G2TUL[=Y+N<AI%I\1M8\<?#CQAKZ>($U".VU2TD9-("B.3SV%O',BV[&*
M.5=@,C 849#*<L=(\M)5E32<I4X-7>CDM6KW2T>MKK73;0*T9U:]*4KJ$:DU
M=+51:LFE9MWVO9_?J4M>^+WQE\-> _$>L:M=3:1>P62LT-QI,I%K<_:HU_<R
M-8I 4*,PVF:<G@JW6M(PH.=."=TY17FTT[IK1_=%6\Q*KB;3E45FHS=NFBO%
MIV:];R:=]D]#W?X.:YXKUN^\5G67U&[T!)X?['O=7T\65U*#$#,IC$<9**_"
ML4!//+=:Y<1"*P^WO^\M-=/LM]F];K\$;X6I4G4;;;C:+U5O>>Z6UUMK^+/%
M_"MQK.B_LQZSX5B\,:VWBH7-S-'87OA>YN(9%:\WC_6P-"^4.0"3^8KJ]V=7
M"NZLN12UM;OYJW=;;DN3@\6K.\G4<=&T_==NEM>SWVUN=?J?B'XJ1^+[I;1]
M9BTE/%EKID5O%I$1A_LV2$>9,&,!8A'Z2;MH/#9'%94(PFH^T>K]K=]K/W/O
M\]R9SKPY^1:15*RMH[VYU\NMMO(Y#Q18_$KQ_I)TS4]*OKFZCMO$5BFHSZ)"
MEQ(BA1:_O3#B/S5RN8]@<=.1D9>XZ7M+6;A3;2O\7/[R[NR5^5WL]2E[:594
MI:I5)Q3:7PNF^65[66KMS)*^VI8CUWXI^&_ ?@;3/#XUJUTZ/11'<7MYH\OV
MFWOD55%O)"FGS/Y* <$1 OC_ %V>O;7E"IBJLVTUHX]I*[NWJK/RO&RUL^G'
M0]M2PE*,4T[M2TUCHK)>Z]-];2UTNBK\2+CXC>.Q%::S8:O)]FU;1[BST_2M
M$F^PRP_(\]RTKP>8K*Y8>6[(5 ^9.X5"-*&)IS72<KW:TC9\MK.SNMWJK]@Q
M,L15PU6G);PC:R?O.ZYKW5U9K1:.W<^GM%\2P>+-+U.>SM[F.&WN;BR5YT \
MYHF*,R8))7<& )P3M/&,$^17@WA[K[4;I==;V^]:KR:/?I37M7'^5I7Z=&_N
MV?FF>&6/C/Q3H_P9\':+X:TK7;+5["&W@U=KC1+R"2VB$9#&)GLYED;>$!V1
M2G!)P!\P].ORU,2YW]Q^?6RLK;VWOMK975]?-C.4*4H03Y[M[.UN9W:=K-V:
MLM;ZM)VL;>B:]\49H] LYWEN6UQ$5M233FC73!#.QF:02V\3!I8-H7?&H\P'
M:H4@4N6E[1I[1M)Z[IQUBM7]M+KS<LG=WB0IU_9<RU<KQ6FSYM).\5]F_11;
MC'3WSCO$VK?%'Q/#XITG5+.Z>WD6X0Z:EA<.FU9E\DV\B6*H25 )S=2Y!. I
M& L*J?[B<MU*FWY/GCS7U6BU^R]D[M7;SQDJ[5>G%:.-1):ZKDERVM%^\W;[
M2W:Y4[)>L_'>QTW5/#*6=[X?35[F59/LEU-X;DUN.UDP,_NH_G1F!(5_N@C+
M=@>*TG)\FCMT?*WY*6R=[.[_ .&]6?+R+G5U=;KF2\W%:O2ZT[G!7^EZ?=:K
MX)L]0\):WI>MV5KIL]SX@?2KO49X?+P?LD5S#$P5B05E<E%VL<AB?E]+F_VJ
MI4IR5N:7DI75NOV5>^[U735GD\JCA:5.I%\W*M;.7*D^EE\3]$TM]DCV2U\=
M1:GX/U/7['3=0GBM?M*PVPAW371A9ES$BDDAV0[>A((..:\RHIJG%PWDDU_V
M]M?MNF^RWZGLTY1G.47M%M-^F]N]G=>;6G0\%\.:;\2?A3:ZO(^CS-=:['!J
M]Q+I#2:D5NUN8S=[U:%=CR02$+&N_P#U)VDG%>@G17+0O[L)+YQ:L]=W[RYG
MHG[S>VWE+V]Y8AQLYQEI>[4DG*":M963Y-VGRI/?77\1^/\ Q[>7FHW>G'Q)
M::5_:KI965OX?EBNY[86]N5*O)8SH@\QIN)ECR3S(@0BHI0BN15+-N]]5;XY
M6OJOLVVDK+75M&M:I.3DZ;:C[MM'_+KT;6O>+[*PG@VU\9:7KYTBUU'Q-IXO
M_$U_)?\ VC1X6@MK62.YECEBG^S^6S,_EY.]U#;05 )5BFHNE",K6C!^3YE*
M*2L^C3;VU3=GHK*;J1G*4;WE*'33E<%?5+HU;?IKU;P_B)KGQ$UV?Q9H5O8>
M)+_0[C3]2LWM[[3MQ+K"WDO$T5C&N'9?EVSS9#@%5/ K#*$G"I.R]Z$EY?O(
M73N^D6^FROS.SO->56,W3A=JTHO3?]W+56CUDE]I:NW*KJVSXM\0>._#]AJT
M&AZ;K5C>S:O>/;W&G:6@AD18H?+\W;8W#.68MARJ!MK!I1@5@G>,7O92=G_U
M\GLKKI9VNKWNDVVQ0YXJ2LU=P5TO^G4+W=I.U[J_+*S7+HE8[7XB64OBKX8^
M&9M=M;X7+&VNKNTAT:348?-,1W)=6:?O)(MS<HO((4\8R+JQA3Q<E3LXIR2O
MJK=->]MGL;4I5*N"BZR:E)1OIJGHWIVOHUO;0\[N?$7BKPCX2*6.G:GX*T2&
MVU"YM[CP]H#LMQ.FSR=]M/%,;*%AO;:P4#'WU[S4E[KE)WDDK)NZWE>\M+M+
MEMKUMK;2**:E&$8V@Y.[C%I[1M:+O:[<D]'K%/3FUZ&R^(_CC;%;/9:W>W4^
MJZ?-%-:Z/N@?3GM86FQ,(_*!,IEZMN7/91QK6IPC-I+X?:I]].?DM??[-NC>
MCU=GC2K5ITHMZN2HM.UUJX>TO9::<U[[+5::K'\-^-OBGJ+7R"+74MI+C2S;
MRZGI6Z>%9+L)<HW^@VRG;%RVU7"C)$I'(J-.FW&,FMW=KJN236[_ )DK74=6
MDT[V'*K7M.44]M$UL^:/9)?"WLY;.ST->/Q+\1]"^*#6&HWEW)X>M;H#S[JR
M=XKFR$>YI6>WT\QK+G=R;B-1M ,?.3A"5)495*BV4KKM:]K7:WLF_BO=VL]%
MO4^L>W5.GJFXV\[M<U[1>UVEK'9-W5V_2]8\06'B+X6SZS=Z#JM_IM[8"X;1
MH[<O>31L,B/RXV.6((^4'OSWK*M3=*?LY:M->E[]?)/?=>J.NC5C6I^TB_=:
M?K;75==5MUU6S/ [OPO//HFG-INE7&G^'9M8FO=2T"3PCJ$UA:DVZK!$+(+
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M^>]E<]-KE.\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * *>L:)IWB+3I=/U6PM=3L)L>9:WD*RQ/@@C*L"#@@'D=J
M:=FI+=;>0/5-/9EM5"*%4!5 P !P!0W?5B2459"TAA0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
